Lobbying Information
Subject Matters
- Health
- Industry
- Intellectual Property
Subject Matter Details
Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
- Industry
Patent Act, R.S.C., 1985, c. P-4. The Act as a whole falls under the jurisdiction of the Minister of Industry, with the exception of sections 79 to 103 pertaining to the Patented Medicines Pricing Review Board (PMPRB), which are the responsibility of the Minister of Health. The Minister of Health has launched a public consultation process which may amend the act, change regulations, and/or result in new policies or programs. Alexion Pharma Canada is participating in these consultations, and will raise awareness on how proposed changes will impact the life sciences industry in Canada and specifically development of innovative new treatments for rare diseases
Policies or Program
- Research and Development
General awareness on the importance of a strong research and development ecosystem in Canada to support ultra rare disease patients
- Science and Technology
The importance of including science and technology, and Canada's innovation potential, in federal policies
Regulation
- Health -
Patent Act, R.S.C., 1985, c. P-4. The Act as a whole falls under the jurisdiction of the Minister of Industry, with the exception of sections 79 to 103 pertaining to the Patented Medicines Pricing Review Board (PMPRB), which are the responsibility of the Minister of Health. The Minister of Health has launched a public consultation process which may amend the act, change regulations, and/or result in new policies or programs. Alexion Pharma Canada is participating in these consultations
- Intellectual Property
Amendments to the Food and Drugs Act: Guide to New Authorities (power to disclose information). Alexion wishes to raise awareness of the importance of considering intellectual property protection when deciding whether to make Confidential Business Information available to third-parties as Health Canada considers guidelines for the bill formerly referred to as C-17.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Patented Medicine Prices Review Board (PMPRB)
In-house Corporation Details
Description of activities
Alexion pharma researches and develops treatments for ultra-rare, life threatening diseases
Responsible officer name and position during the period of this registration
Sean Richardson,
Vice President and General Manager, Alexion Pharma Canada
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
3100 Rutherford Road
Vaughan, ON L4K 0G6
Canada
Telephone number:
416-356-3022
Parent Company Information
- Alexion Pharma Inc.
-
100 College Street
New Haven, CT 06510
United States of America
Subsidiary Beneficiary Information
Alexion Pharma Canada does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Sean Richardson,
Vice President and General Manager, Alexion Pharma Canada |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Jason Locklin,
Director, Global Government Affairs |
No public offices held
